Astellas Pharma’s Izervay lowers GA lesion growth in Phase 3 GATHER2 trial
The results were consistent across every month and every-other-month dosing of Izervay against sham through two years of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Nov 23
The results were consistent across every month and every-other-month dosing of Izervay against sham through two years of…
06 Nov 23
PM8002 is currently undergoing Phase 2 studies in China to assess its efficacy and safety as a monotherapy…
03 Nov 23
The extended collaboration with the Broad Institute of MIT and Harvard, which aims to identify cancer targets and…
03 Nov 23
The approved Type II Variation application pertains to the use of Ryeqo in women who have a history…
03 Nov 23
Through the drug product business, Cambrex has been delivering services around product development, clinical and commercial manufacturing, and…
03 Nov 23
The reduction in systolic blood pressure during treatment in the Phase 4 trial was more significant at Week…
03 Nov 23
The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame…
02 Nov 23
Under the terms of the agreement, AstraZeneca will use Cellectis’ patented gene editing technologies and manufacturing expertise to…
02 Nov 23
The anti-PD-1 therapy delivered a statistically significant improvement in OS as an adjuvant treatment in RCC patients at…
02 Nov 23
Under the agreement, AbbVie will have the option to purchase a co-exclusive license to develop, produce, and market…